使用124I-依武扎米肽(124I-P5+14)与18F-氟比他匹对心脏淀粉样变定量的比较:一项初步PET/CT研究
这项初步PET/CT研究纳入46名参与者(12例AL型、12例ATTRwt型、2例遗传性心脏淀粉样变及20名对照),比较124I-依武扎米肽与18F-氟比他匹定量心肌摄取的能力。124I-依武扎米肽左心室%ID在心脏淀粉样变患者与对照间差异显著,能准确区分心脏淀粉样变与对照;在ATTRwt型中124I-依武扎米肽摄取高于18F-氟比他匹,且与心脏结构功能指标相关。
要点
- 124I-依武扎米肽左心室%ID可准确区分心脏淀粉样变患者与对照。
- ATTRwt型心脏淀粉样变中124I-依武扎米肽左心室%ID高于18F-氟比他匹。
- 124I-依武扎米肽摄取与室间隔厚度、左室质量指数等结构功能指标相关。
核心结论
- 124I-依武扎米肽被心脏淀粉样物摄取,能准确区分心脏淀粉样变与对照;AL型中区分能力与18F-氟比他匹相似,ATTRwt型中可能更优;其摄取与心脏结构功能指标呈中至强相关,提示可有效定量淀粉样物。
研究设计与样本
- 初步PET/CT研究,纳入46名参与者:12例AL型心脏淀粉样变、12例ATTRwt型心脏淀粉样变、2例遗传性淀粉样变及20名对照;淀粉样变患者均行124I-依武扎米肽和18F-氟比他匹PET/CT,对照接受124I-依武扎米肽(n=10)或18F-氟比他匹(n=8)PET/CT。
诊断标准与关键数值
- 以Youden指数定义左心室%ID高值;124I-依武扎米肽左心室%ID中位数:AL型1.48(IQR 1.12-1.89),ATTRwt型2.12(IQR 1.66-2.47),对照0.00(IQR 0.00-0.01),总体P<0.001;高左心室%ID能完全区分心脏淀粉样变与对照,18F-氟比他匹区分能力相似;ATTRwt型中124I-依武扎米肽左心室%ID高于18F-氟比他匹(P=0.002)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
BACKGROUND: Cardiac amyloid quantification could advance early diagnosis of amyloid cardiomyopathy (CMP) and treatment monitoring. However, current imaging tools are based on indirect measurements. 124I-evuzamitide is a novel pan-amyloid radiotracer binding to amyloid deposits from multiple amyloidogenic proteins. Its ability to quantify cardiac amyloid has not yet been investigated.
OBJECTIVES: The objectives of this pilot study were to quantify myocardial 124I-evuzamitide uptake and to compare its diagnostic value to 18F-florbetapir in participants with amyloid CMP and control subjects.
METHODS: This study included 46 participants: 12 with light-chain (AL) CMP, 12 with wild-type transthyretin (ATTRwt) CMP, 2 with hereditary amyloidosis, and 20 control subjects. All amyloidosis participants underwent positron emission tomography/computed tomography with 124I-evuzamitide and 18F-florbetapir. Control subjects underwent 124I-evuzamitide (n = 10) or 18F-florbetapir (n = 8) positron emission tomography/computed tomography. Left ventricular percent injected dose (LV% ID) was measured as mean activity concentration × myocardial volume/injected activity. High LV %ID was defined using Youden's index.
RESULTS: In CMP participants, median age was 74 years and 92% were men. 124I-evuzamitide LV %ID differed across groups: median AL-CMP 1.48 (IQR: 1.12-1.89), ATTRwt-CMP 2.12 (IQR: 1.66-2.47), and control subjects 0.00 (IQR: 0.00-0.01; overall P < 0.001). High LV %ID perfectly discriminated CMP from control subjects. Discrimination performance was similar for 18F-florbetapir LV %ID. Notably, for ATTRwt-CMP, LV %ID was higher with 124I-evuzamitide than 18F-florbetapir (P = 0.002). 124I-evuzamitide LV %ID was correlated with interventricular septum thickness (Spearman's ρ = 0.78) and LV global longitudinal strain (ρ = 0.54) from echocardiography, and with LV mass index (ρ = 0.82) and extracellular volume (ρ = 0.51) from cardiac magnetic resonance.
CONCLUSIONS: 124I-evuzamitide demonstrates uptake by cardiac amyloid and accurately discriminates amyloid CMP from control subjects. In AL-CMP, discrimination performance is similar to 18F-florbetapir. In ATTRwt-CMP, performance may be better with 124I-evuzamitide. Moderate-to-strong correlations of 124I-evuzamitide uptake with cardiac structural and functional metrics suggest valid amyloid quantification. Hence, 124I-evuzamitide is a promising novel radiotracer to detect and quantify cardiac amyloid.
引用
- Clerc OF, Cuddy SAM, Robertson M, et al. Cardiac Amyloid Quantification Using 124I-Evuzamitide (124I-P5+14) Versus 18F-Florbetapir: A Pilot PET/CT Study. JACC Cardiovasc Imaging. 2023. PMID: 37676210. doi:10.1016/j.jcmg.2023.07.007
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。